Compare Abeona Therapeutics Inc (ABEO) vs Bristol-Myers Squibb Co (BMY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Bristol-Myers Squibb Co — how do they compare? Abeona Therapeutics Inc trades at $5.57 (market cap $319.66M), while Bristol-Myers Squibb Co trades at $62.86 (market cap $128.36B). The key difference: Bristol-Myers Squibb Co is far larger — about 401.6× Abeona Therapeutics Inc's market cap, and Bristol-Myers Squibb Co pays a 4.01% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Abeona Therapeutics Inc for 22 Days and Bristol-Myers Squibb Co for 93 Days on average.
| ABEO | BMY | |
|---|---|---|
Market Cap | $319.66M | $128.36B |
Volume | 3,459,993 | 12,132,088 |
Sector | Health | Health |
52-Week High | $7.46 | $68.09 |
52-Week Low | $4.17 | $42.60 |
Typical Hold Time | 22 Days | 93 Days |
Enterprise Value | $192.70M | $162.35B |
Dividend Yield | — | 4.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $5.60, up 4.28% today, but faces a bearish technical outlook with strong sell signals from moving averages. The company reported a net loss of $63M in 2026 with a negative net margin of -246.43%, though quarterly EPS has shown some beats. Recent news highlights ongoing legal investigations and operational challenges, but also expansion of treatment centers and positive Medicare payment status for ZEVASKYN.
The investment case balances deep value from low EV/EBITDA of 3.82 and strong analyst buy ratings (66.7% consensus) against severe profitability issues and legal overhangs. Upside hinges on successful commercialization of ZEVASKYN, while downside risks include persistent losses and litigation outcomes.
Bristol Myers Squibb (BMY) trades at $62.71, down 1.4% on the day, with a bullish technical signal despite recent weakness. The stock shows strong fundamentals with a P/E of 13.84, net income margin of 18.87%, and consistent earnings beats in recent quarters. Recent positive clinical trial results for Sotyktu and arlocabtagene autoleucel highlight pipeline progress, while the company maintains a solid dividend yield.
BMY presents a compelling value opportunity with attractive valuation metrics and strong profitability, though patent expirations and debt levels pose risks. Analyst consensus targets $70.00 with 48% buy ratings, suggesting 12% upside potential. The company's growth portfolio now represents 58% of revenue, offsetting legacy product declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →
